Hemato-Oncology Testing Market Forecast Driven by Precision Diagnostics
Author : Prasad Shinde | Published On : 16 Nov 2026
Diagnosing blood cancer requires more than identifying abnormal blood cell counts. Clinicians increasingly depend on molecular and genetic information to classify malignancies, assess disease progression, identify treatment-relevant mutations, and determine whether cancer cells remain after therapy. Hemato-oncology testing brings together specialized diagnostic methods that help healthcare professionals make these decisions with greater precision.
The hemato-oncology testing market was valued at USD 4.5 billion in 2025 and is estimated to reach USD 5.1 billion in 2026. The market is projected to reach USD 10.9 billion by 2033, expanding at a CAGR of 11.5% from 2026 to 2033. Increasing blood cancer prevalence, advances in molecular testing, and the growing use of personalized treatment approaches are major factors contributing to this expansion.
A More Detailed Understanding of Blood Cancer
Leukemia, lymphoma, and myeloproliferative neoplasms involve different biological changes that require specialized diagnostic evaluation. Conventional blood tests and bone marrow examinations remain important, but molecular techniques provide additional information about genetic abnormalities and disease characteristics.
Lymphoma accounted for the largest cancer segment share, representing 46.7% of market revenue in 2025. Its diagnostic requirements include identifying specific disease subtypes, evaluating biomarkers, and assessing genetic changes that can influence treatment selection. Immunohistochemistry, flow cytometry, PCR, and genomic profiling are among the methods used in this process.
Leukemia testing also represents a substantial clinical application. Complete blood counts, bone marrow examinations, cytogenetic analysis, and molecular assays help distinguish leukemia subtypes and monitor treatment response. Testing for genetic alterations such as BCR::ABL1 is particularly important in the diagnosis and management of chronic myeloid leukemia.
Go Deeper! Ask Prism AI about the Hemato Oncology Testing Market.
Why Specialized Testing Services Lead Revenue
The services category held 58.2% of market revenue in 2025, making it the leading product segment. Specialized laboratories provide diagnostic testing, genomic profiling, biomarker analysis, sample processing, and disease monitoring. These services are valuable for healthcare facilities that do not have the infrastructure or expertise to perform every advanced molecular procedure internally.
Assay kits and reagents form the other major product category. They include primers, probes, antibodies, controls, and consumables required for molecular and immunological testing. Increasing test volumes and the adoption of more sophisticated diagnostic procedures support demand for these products.
The relationship between laboratory services and testing consumables is important: advanced diagnostic methods require both specialized expertise and reliable testing materials to deliver consistent results.
PCR Remains Established as NGS Gains Momentum
PCR accounted for 31.1% of technology-segment revenue in 2025. Its sensitivity, established clinical use, and ability to detect specific genetic alterations make it a widely used method in blood cancer diagnosis. Real-time quantitative PCR and digital PCR also support the measurement of molecular response and the detection of residual disease.
Next-generation sequencing (NGS) is expected to register the fastest technology-segment growth, with a projected CAGR of 12.7% during the forecast period. Unlike tests designed to identify a limited number of mutations, NGS can examine multiple genetic alterations within a single workflow. This capability supports comprehensive genomic profiling, risk assessment, and treatment selection.
Minimal residual disease testing is another important area of development. Highly sensitive molecular methods can identify small amounts of remaining cancer after treatment, providing information that may help clinicians evaluate response and monitor relapse risk.
Hospitals Remain Central to Clinical Adoption
Hospitals accounted for 75.0% of market revenue in 2025. Their diagnostic laboratories support patient evaluation across oncology departments, hematology units, and specialized treatment centers. Hospitals also coordinate testing with treatment decisions, making timely and accurate diagnostic results particularly important.
Academic and research institutes contribute through biomarker discovery, clinical studies, and the development of new diagnostic approaches. Their work supports the validation of emerging methods and the investigation of genetic changes associated with different blood cancer types.
The market also benefits from growing collaborations between diagnostic developers, healthcare institutions, and pharmaceutical companies. Companion diagnostics can help identify patients who may benefit from particular targeted therapies, strengthening the connection between diagnostic testing and precision medicine.
The Practical Barriers Behind Advanced Diagnostics
Despite technological progress, advanced hemato-oncology testing involves considerable infrastructure and expertise requirements. NGS platforms, digital PCR systems, and comprehensive molecular assays can be expensive to implement. Smaller laboratories may also face challenges involving skilled personnel, sample handling, quality control, and interpretation of complex genomic results.
Regulatory validation and reimbursement limitations can further affect adoption. Standardized testing procedures, improved laboratory capabilities, and more accessible diagnostic services will be important in addressing these barriers.
As molecular profiling and disease monitoring become increasingly integrated into blood cancer care, hemato-oncology testing is taking on a broader role in clinical decision-making. Its importance extends from initial diagnosis to treatment selection and ongoing assessment of patient response.
Request a Sample Report to Explore Detailed Market Insights and Industry Analysis.
Key Hemato Oncology Testing Companies:
- F. Hoffmann-La Roche Ltd
- Abbott
- EntroGen, Inc.
- Qiagen N.V.
- Cepheid (Danaher Corporation)
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Illumina, Inc.
- Amoy Diagnostics Co., Ltd.
- ASURAGEN, INC
- ArcherDX, Inc. (IDT)
About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.
